---
figid: PMC9604078__ijms-23-12587-g001
figtitle: Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor
  Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia
organisms:
- NA
pmcid: PMC9604078
filename: ijms-23-12587-g001.jpg
figlink: /pmc/articles/PMC9604078/figure/ijms-23-12587-f001/
number: F1
caption: Schematic representation of signaling pathways in myeloid cells. The inducible
  growth factor receptor FLT3 signals via PI3K-AKT-mTOR and RAS-MEK-ERK (black arrows).
  FLT3-ITD, a constitutively active growth factor receptor, additionally induces PTPN11-STAT5
  (red arrows). Activated cytokine receptors signal via Janus kinase (JAK)-signal
  transducer and activator of transcription (STAT) pathway. Signal transduction leads
  to inhibition of the tumor suppressor p53 and induction of the anti-apoptotic BH3
  proteins BCL2, BCL-XL, and MCL1, thereby promoting proliferation and cell growth
  of myeloid cells. Oncogenic functions are indicated in red, tumor suppressor functions
  in green, chemical inhibitors in blue.
papertitle: Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor
  Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
reftext: Katja Seipel, et al. Int J Mol Sci. 2022 Oct;23(20):12587.
year: '2022'
doi: 10.3390/ijms232012587
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI
keywords: acute myeloid leukemia (AML) | B-cell lymphoma-2 (BCL2) | venetoclax (ABT-199)
  | isocitrate dehydrogenase 2 (IDH2) | bimiralisib (PQR309) | mammalian target of
  rapamycin (mTOR) | phosphoinositide 3-kinase (PI3K) | Fms-related receptor tyrosine
  kinase 3 (FLT3) | protein tyrosine phosphatase non-receptor type 11 (PTPN11)
automl_pathway: 0.9082295
figid_alias: PMC9604078__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC9604078__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9604078__ijms-23-12587-g001.html
  '@type': Dataset
  description: Schematic representation of signaling pathways in myeloid cells. The
    inducible growth factor receptor FLT3 signals via PI3K-AKT-mTOR and RAS-MEK-ERK
    (black arrows). FLT3-ITD, a constitutively active growth factor receptor, additionally
    induces PTPN11-STAT5 (red arrows). Activated cytokine receptors signal via Janus
    kinase (JAK)-signal transducer and activator of transcription (STAT) pathway.
    Signal transduction leads to inhibition of the tumor suppressor p53 and induction
    of the anti-apoptotic BH3 proteins BCL2, BCL-XL, and MCL1, thereby promoting proliferation
    and cell growth of myeloid cells. Oncogenic functions are indicated in red, tumor
    suppressor functions in green, chemical inhibitors in blue.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IDH2
  - TET2
  - FOXG1
  - FOXH1
  - FOXM1
  - FOXQ1
  - FOXS1
  - FOXA1
  - FOXA2
  - FOXA3
  - FOXB1
  - FOXB2
  - FOXC1
  - FOXC2
  - FOXD1
  - FOXD2
  - FOXD3
  - FOXD4
  - FOXE1
  - FOXE3
  - FOXF1
  - FOXF2
  - FOXI1
  - FOXI2
  - FOXI3
  - FOXJ1
  - FOXJ2
  - FOXJ3
  - FOXK1
  - FOXK2
  - FOXL1
  - FOXL2
  - FOXN1
  - FOXN2
  - FOXN3
  - FOXN4
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - FOXP1
  - FOXP2
  - FOXP3
  - FOXP4
  - FOXR1
  - FOXR2
  - FOXD4L1
  - FOXD4L3
  - FOXD4L4
  - FOXD4L5
  - FOXD4L6
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - PDK1
  - PDPK1
  - MTOR
  - BMI1
  - COMMD3-BMI1
  - CDKN1A
  - CDPF1
  - FLT3
  - PTPN11
  - TP53
  - MCL1
  - KRAS
  - HRAS
  - NRAS
  - BCL2
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - STAT3
  - BCL2L11
  - MAP2K1
  - EPHB2
  - MAPK1
  - MAPK3
  - MDM2
  - MAP2K7
  - MAP2K2
---
